A phase II trial of Arimidex [anastrozole] plus Zoladex [goserelin] in the treatment of hormone receptor positive, metastatic carcinoma of the the breast in premenopausal women

Trial Profile

A phase II trial of Arimidex [anastrozole] plus Zoladex [goserelin] in the treatment of hormone receptor positive, metastatic carcinoma of the the breast in premenopausal women

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2013

At a glance

  • Drugs Anastrozole (Primary) ; Goserelin (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Dec 2012 Planned End Date changed from 1 Dec 2013 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 02 Jun 2010 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top